



NOVARTIS PHARMACEUTICALS CORPORATION
 East Hanover, NJ 07936

MASTER CLINICAL TRIAL AGREEMENT (CTA) - AMENDMENT #1

The following is Amendment # 1 ("Amendment #1") to the Master Clinical Trial Agreement (the "Agreement"), dated September 1, 1998 between Novartis Pharmaceuticals Corporation ("Novartis") and The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas M.D. Anderson Cancer Center, The University of Texas Southwestern Medical Center at Dallas, The University of Texas Medical Branch at Galveston and The University of Texas Health Center at Tyler, each with an office and place of business as set forth in Article 12 of the Master Clinical Trial Agreement and each a component of The University of Texas System, located at 201 West 7th Street, Austin, Texas 78701 (each an Institution hereinafter collectively "Institution").

The parties wish to amend the Agreement to extend the term from September 1, 2003 to December 31, 2003. Thus, Article 2 of the Agreement is hereby amended to reflect that the term of the Agreement is extended 4 additional months from September 1, 2003 until December 31, 2003.

All remaining obligations and responsibilities of the Institution as outlined in the Agreement are to remain unchanged.

In witness whereof, the parties hereto have executed this Amendment #1 in duplicate by proper persons thereunto duly authorized.

NOVARTIS PHARMACEUTICALS CORPORATION

By: *Sheila Straub*
 Name: Sheila Straub
 Title: Vice President,
 US International Clinical Research Operations

Date: 10/31/03

THE UNIVERSITY OF TEXAS HEALTH CENTER AT TYLER

By: *Rick Heffner*
 Mr. Rick Heffner
 Vice President for Finance and Administration

Date: 10/20/03

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON

By: _____
 Devin S. Longuet
 Legal Officer

Date: _____



NOVARTIS PHARMACEUTICALS CORPORATION
 East Hanover, NJ 07936

MASTER CLINICAL TRIAL AGREEMENT (CTA) - AMENDMENT #1

The following is Amendment # 1 ("Amendment #1") to the Master Clinical Trial Agreement (the "Agreement"), dated September 1, 1998 between Novartis Pharmaceuticals Corporation ("Novartis") and The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas M.D. Anderson Cancer Center, The University of Texas Southwestern Medical Center at Dallas, The University of Texas Medical Branch at Galveston and The University of Texas Health Center at Tyler, each with an office and place of business as set forth in Article 12 of the Master Clinical Trial Agreement and each a component of The University of Texas System, located at 201 West 7th Street, Austin, Texas 78701 (each an Institution hereinafter collectively "Institution").

The parties wish to amend the Agreement to extend the term from September 1, 2003 to December 31, 2003. Thus, Article 2 of the Agreement is hereby amended to reflect that the term of the Agreement is extended 4 additional months from September 1, 2003 until December 31, 2003.

All remaining obligations and responsibilities of the Institution as outlined in the Agreement are to remain unchanged.

In witness whereof, the parties hereto have executed this Amendment #1 in duplicate by proper persons thereunto duly authorized.

NOVARTIS PHARMACEUTICALS CORPORATION

By: *Sheila Straub*
 Name: Sheila Straub
 Title: Vice President,
 US International Clinical Research Operations

Date: 10/31/03

THE UNIVERSITY OF TEXAS HEALTH CENTER AT TYLER

By: _____
 Mr. Rick Hefner
 Vice President for Finance and Administration

Date: _____

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON

By: *Catherine Moore*
 Catherine Moore, Director
 Office of Sponsored Projects

Date: 10-7-03

**THE UNIVERSITY OF TEXAS HEALTH
SCIENCE CENTER AT SAN ANTONIO**

By: Jane Youngers
Jane Youngers
Director, Grants Management

Date: 10-6-03

**THE UNIVERSITY OF TEXAS M.D.
ANDERSON CANCER CENTER**

By: _____
~~Leonard A. Zwelling, M.D., M.B.A.~~
~~Vice-President for Research Administration~~

Date: _____

**THE UNIVERSITY OF TEXAS MEDICAL
BRANCH AT GALVESTON**

By: _____
Barbara DeHaven, MPA
Director of Sponsored Research
Date: _____

**THE UNIVERSITY OF TEXAS
SOUTHWESTERN MEDICAL CENTER AT
DALLAS**

By: _____
Perrie M. Adams, Ph.D.
Associate Dean for Research


Date: _____

**THE UNIVERSITY OF TEXAS HEALTH
SCIENCE CENTER AT SAN ANTONIO**

By: _____
Jane Youngers
Director, Grants Management

Date: _____

**THE UNIVERSITY OF TEXAS M.D.
ANDERSON CANCER CENTER**

By:  _____
Melinda Mathis, M.P.A.
Director, Sponsored Programs & Compliance

Date: 10-6-03

**THE UNIVERSITY OF TEXAS MEDICAL
BRANCH AT GALVESTON**

By: _____
Barbara DeHaven, MPA
Director of Sponsored Research

Date: _____

**THE UNIVERSITY OF TEXAS
SOUTHWESTERN MEDICAL CENTER AT
DALLAS**

By: _____
Perrie M. Adams, Ph.D.
Associate Dean for Research

Date: _____

**THE UNIVERSITY OF TEXAS HEALTH
SCIENCE CENTER AT SAN ANTONIO**

By: _____

Jane Youngers
Director, Grants Management

Date: _____

**THE UNIVERSITY OF TEXAS M.D.
ANDERSON CANCER CENTER**

By: _____

~~Leonard A. Zwelling, M.D., M.B.A.
Vice-President for Research Administration~~

Date: _____

**THE UNIVERSITY OF TEXAS MEDICAL
BRANCH AT GALVESTON**

By: Barbara DeHaven

Barbara DeHaven, MPA
Director of Sponsored Research

Date: 10.7.03

**THE UNIVERSITY OF TEXAS
SOUTHWESTERN MEDICAL CENTER AT
DALLAS**

By: _____

Perrie M. Adams, Ph.D.
Associate Dean for Research

Date: _____

**THE UNIVERSITY OF TEXAS HEALTH
SCIENCE CENTER AT SAN ANTONIO**

By: _____
Jane Youngers
Director, Grants Management

Date: _____

**THE UNIVERSITY OF TEXAS M.D.
ANDERSON CANCER CENTER**


By: _____
~~Leonard A. Zwelling, M.D., M.B.A.~~
~~Vice President for Research Administration~~

Date: _____

**THE UNIVERSITY OF TEXAS MEDICAL
BRANCH AT GALVESTON**

By: _____
Barbara DeHaven, MPA
Director of Sponsored Research
Date: _____

**THE UNIVERSITY OF TEXAS
SOUTHWESTERN MEDICAL CENTER AT
DALLAS**

By:  _____
Perle M. Adams, Ph.D.
Associate Dean for Research

Date: 10/8/03

Contact List

Melinda Mathis, MPA
Director
Sponsored Programs and Compliance
Office of Research Administration
UT M.D. Anderson Cancer Center
1515 Holcombe Boulevard, Unit 307
Room B8.4453
Houston, TX 77030

phone: 713-745-3468
fax: 713-794-4535
email: mmathis@mdanderson.org
Tax ID: 74-6001118

Kathryn A Bradley
Senior Grants/Contracts Specialist
The University of Texas Health
Science Center at Houston
P.O. Box 20036
Houston, TX 77225

phone: 713-500-3073
fax: 713-500-0355
email: Kathryn.A.Bradley@uth.tmc.edu
Tax ID: 74-1761309

Overnight address is:

7000 Fannin Street, Suite 1006D
Houston, TX 77030

Lively Williams
Clinical Trial Specialist
The University of Texas Medical
Branch at Galveston
Office of Clinical Trials
301 University Boulevard
2.234 Gail Bordon
Galveston, TX 77555-0671

phone: (409) 772-1538
fax: (409) 747-3793
email: hlwillia@utmb.edu
Tax ID: 74-6000949

Perrie Adams, Ph.D.
Assoc. Dean for Research
The University of Texas Southwestern
Medical Center at Dallas
5323 Harry Hines Blvd., B1.204
Dallas, TX 75390-9016

phone: 214-648-6449
fax: 214-648-3362
email: perrie.adams@utsouthwestern.edu
Tax ID: 75-6002868

Rick Hefner
Vice President for Finance and Administration
The University of Texas Health Center at Tyler
11937 U.S. Hwy. 271
Tyler, TX 75708

phone: 903-877-7720
fax: 903-877-7899
email: rick.hefner@uthct.edu
Tax ID: 75-600-1354

Jane A. Youngers
Director, Grants Management
The University of Texas Health Science
Center at San Antonio
7703 Floyd Curl Drive, Mail Code 7828
San Antonio, TX 78229-3900

phone: 210-567-2333
fax: 210-567-2344
email: youngers@uthscsa.edu
Tax ID: 74-1586031